Genfit stock among the strongest gains in the SBF 120 following its quarterly results
The Lille-based biotech company specializing in hepatic and metabolic diseases is regaining ground this Wednesday, posting one of the sharpest rebounds in the index. This upturn occurs in a context of high recent volatility, against a backdrop of short-selling positions showing marked progression over the past month.
A clear technical rebound but a stock still below its two first moving averages
Genfit gains 4.75% intra-day at €9.93, against an SBF 120 nearly flat (-0.05%). The stock thus ranks among the strongest gainers in the index, though this rebound only partially offsets the 30.95% decline accumulated over the month. Short-term momentum remains constrained: the price is trading well below the 20-day moving average at €11.81 (gap of -15.92%) and the 50-day moving average at €13.02 (gap of -23.73%), two thresholds that represent significant ceilings for any sustained recovery.
Conversely, the 200-day moving average at €9.47 remains below the current price, offering support 4.86% below current trading levels. The RSI at 31, still close to the oversold zone where it has been trading in recent days, reflects the exhaustion of the selling phase from the recent correction. Resistance at €14.52 remains very distant, while support at €8.92 represents the first safety net in case of a reversal.
Half-yearly results scrutinized and bearish positions showing sharp progression over one month
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The rebound follows the first half of 2026 results published on September 28, which showed cash reserves of €113.8 million and a tripling of royalties from Iqirvo to €21 million. However, the net loss widened to €26.1 million, compared to €10.0 million a year earlier, which had weighed on the stock the previous day. In parallel, institutional selling pressure surged: according to filed declarations, two funds now cumulatively hold 1.27% of capital sold short, a position that increased by 1.27 percentage points over thirty days, starting from zero.
This rapid rise in bearish bets reflects a lack of confidence from a segment of institutional investors regarding the company's prospects, though it is not possible to determine their precise motivation. Over one year, the stock remains up 214.2%, despite a decline of 5.97% over three months, illustrating the extreme volatility characteristic of this biotech value.
SectorPharmacie et biotechnologies›Biotechnologies
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: 9M 2026
Key reported figures
Revenue: 36,4 millions d'euros
Quarterly revenue: 36,4 millions d'euros
Revenue growth: -7,1 %
Guidance from the release
« conforte GENFIT dans son anticipation de la réception possible d'un nouveau paiement d'étape commercial » ; « permettent un financement des activités au-delà de fin 2028 »
Risks mentioned
Dépendance envers Ipsen pour la majorité des revenus (redevances sur ventes d'Iqirvo), qui représente 99,7% des revenus de redevances
Paiements d'étape commerciaux futurs soumis à conditions réglementaires et commerciales incertaines
Besoin de financement au-delà de 2028 dépendant de la croissance des ventes d'élafibranor et de l'adoption commerciale des technologies NIS™
Opportunities identified
Croissance des ventes d'Iqirvo auprès d'Ipsen (188% YoY sur redevances) avec pic de ventes révisé à 1 milliard d'euros
Medicare a approuvé le remboursement du test NASHnext® en août 2026, ouvrant un marché potentiel estimé à plus de 1,5 milliard de dollars à horizon 2033
Lancement de trois essais cliniques de Phase 2 (ACLF, CCA) avec résultats attendus en 2027
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.